Last reviewed · How we verify
Cannabidiol oral oil
Cannabidiol modulates endocannabinoid signaling and multiple other pathways to produce anxiolytic, anti-inflammatory, and neuroprotective effects.
Cannabidiol modulates endocannabinoid signaling and multiple other pathways to produce anxiolytic, anti-inflammatory, and neuroprotective effects. Used for Seizure disorders (Dravet syndrome, Lennox-Gastaut syndrome), Anxiety disorders, Epilepsy.
At a glance
| Generic name | Cannabidiol oral oil |
|---|---|
| Also known as | CBD, Cannabidiol + OCP, CBD 5% |
| Sponsor | Hôpital le Vinatier |
| Drug class | Cannabinoid |
| Target | Multiple (5-HT1A, TRPV1, CB1, CB2, glycine receptors) |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Cannabidiol (CBD) is a non-intoxicating cannabinoid that interacts with multiple molecular targets including serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), and glycine receptors, while also modulating endocannabinoid tone indirectly. It exhibits anti-inflammatory, antioxidant, and neuroprotective properties through these diverse mechanisms. The exact therapeutic mechanism varies by indication but generally involves reduction of neuroinflammation and modulation of neural signaling.
Approved indications
- Seizure disorders (Dravet syndrome, Lennox-Gastaut syndrome)
- Anxiety disorders
- Epilepsy
Common side effects
- Somnolence
- Fatigue
- Diarrhea
- Decreased appetite
- Elevated liver enzymes
Key clinical trials
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- Study of Cannabidiol in Sanfilippo Syndrome (PHASE2, PHASE3)
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Cannabidiol for Reduction of Brain Neuroinflammation (PHASE2)
- Pharmacokinetic Evaluation of a Natural CBD Extract (NA)
- Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study (PHASE1, PHASE2)
- Cannabis (THC vs. CBD) in Multiple Sclerosis (PHASE2)
- Improving Pain Disability With the Use of Oral Cannabinoids (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabidiol oral oil CI brief — competitive landscape report
- Cannabidiol oral oil updates RSS · CI watch RSS
- Hôpital le Vinatier portfolio CI